Description: Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Home Page: www.medicure.com
2-1250 Waverley Street
Winnipeg,
MB
R3T 6C6
Canada
Phone:
204 487 7412
Officers
| Name | Title |
|---|---|
| Dr. Albert David Friesen Ph.D. | Founder, CEO & Chairman of the board |
| Dr. Neil Owens Ph.D. | President & COO |
| Mr. Haaris Uddin B.Com., CPA | Chief Financial Officer |
| Dr. Reuben Saba Ph.D. | Vice President of Scientific & Medical Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 12.1803 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4612 |
| Price-to-Sales TTM: | 0.3303 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |